Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers
BioSpace
As Summit Therapeutics' Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.
pharminent
May 29, 2026 (Last updated: May 29, 2026)
BioSpace
As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.
